BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY

Recruiting

• Conditions: bone loss; osteoporosis; 10013296; 10038364

• Registration Number: NL-OMON37103
• Lead Sponsor: Sint Franciscus Gasthuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 51

Inclusion Criteria

Prostate cancer
androgen deprivation according to Bolla schedule

Exclusion Criteria

osteoporosis
treatment with bisphophonates or RANK-ligand inhibitor

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Compare the change in BMD between the 2 modalities</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>describe course of BMD of both modalities<br /><br>Identify factors that influence the BMD pattern</p><br>